Fanregratinib · ATLED

Small molecule

Also known as HMPL-453

Approvedregulatory verdict

Evidence outlook

Approved: Advanced, metastatic or unresectable intrahepatic cholangiocarcinoma with FGFR2 fusion or... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also approved (1)
CN
  • Advanced, metastatic or unresectable intrahepatic cholangiocarcinoma with FGFR2 fusion or rearrangement after prior systemic therapy (conditional approval)
Product first approved 2026sec.gov

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

No registered studies for this indication.

Competitive landscape

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

This drug's own stage for Cholangiocarcinoma: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Fanregratinib (ATLED): this drugStage not on recordSmall moleculeFGFR1/2/3not yet gradedNo reviewed efficacy summary in this indication
Futibatinib (Lytgobi)ApprovedSmall moleculeFGFR (FGFR1/2/3/4)Weak signalNo reviewed efficacy summary in this indication
Lirafugratinib (Lyrfigtu)ApprovedSmall moleculeFGFR2not yet gradedNo reviewed efficacy summary in this indication
Pemigatinib (Pemazyre)ApprovedSmall moleculeFGFR1/2/3Weak signalNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
TinengotinibPhase 3Small moleculeAurora A/B kinase (with secondary FGFR1/2/3, VEGFR1, JAK1/2, CSF1R inhibition)Weak signalFeatured results are safety only in this race
ToripalimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
CrelosidenibPhase 1Small moleculeMutant IDH1 and IDH2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 August 2026ApprovalChina conditional approval of fanregratinib (ATLED) in FGFR2 intrahepatic cholangiocarcinoma
China, NMPA · HUTCHMED · Source ↗
4 July 2026PresentationFanregratinib pivotal Phase II data at ESMO GI 2026 (343RO)
China · HUTCHMED · Source ↗